FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.
Safety Announcement
[4-9-2019] The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.
While we continue to track this safety concern as part of our ongoing monitoring of risks associated with opioid pain medicines, we are requiring changes to the prescribing information for these medicines that are intended for use in the outpatient setting. These changes will provide expanded guidance to health care professionals on how to safely decrease the dose in patients who are physically dependent on opioid pain medicines when the dose is to be decreased or the medicine is to be discontinued.
Rapid discontinuation can result in uncontrolled pain or withdrawal symptoms. In turn, these symptoms can lead patients to seek other sources of opioid pain medicines, which may be confused with drug-seeking for abuse. Patients may attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
Opioids are a class of powerful prescription medicines that are used to manage pain when other treatments and medicines cannot be taken or are not able to provide enough pain relief. They have serious risks, including abuse, addiction, overdose, and death. Examples of common opioids include codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone.
Health care professionals should not abruptly discontinue opioids in a patient who is physically dependent. When you and your patient have agreed to taper the dose of opioid analgesic, consider a variety of factors, including the dose of the drug, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. No standard opioid tapering schedule exists that is suitable for all patients. Create a patient-specific plan to gradually taper the dose of the opioid and ensure ongoing monitoring and support, as needed, to avoid serious withdrawal symptoms, worsening of the patient’s pain, or psychological distress (For tapering and additional recommendations, see Additional Information for Health Care Professionals).
Patients taking opioid pain medicines long-term should not suddenly stop taking your medicine without first discussing with your health care professional a plan for how to slowly decrease the dose of the opioid and continue to manage your pain. Even when the opioid dose is decreased gradually, you may experience symptoms of withdrawal (See Additional Information for Patients). Contact your health care professional if you experience increased pain, withdrawal symptoms, changes in your mood, or thoughts of suicide.
We are continuing to monitor this safety concern and will update the public if we have new information. Because we are constantly monitoring the safety of opioid pain medicines, we are also including new prescribing information on other side effects including central sleep apnea and drug interactions. We are also updating information on proper storage and disposal of these medicines that is currently available on our
Disposal of Unused Medicines webpage.
To help FDA track safety issues with medicines, we urge patients and health care professionals to report side effects involving opioids or other medicines to the FDA MedWatch program, using the information in the “Contact FDA” box at the bottom of the page.
https://www.fda.gov/Drugs/DrugSafety/uc ... rce=Eloqua
- Forced Tapering of Opioids - Suicides in Despair with Chronic and Intractable Pain Opioid Crisis The FDA the good bad and the ugly
- Search
- Search
-
- It is currently Mon Jan 18, 2021 11:37 pm
- All times are UTC
Health care professionals should not abruptly discontinue opioids in a patient
What we are learning about the FDA in the Opioid Crisis and its motivations.
Health care professionals should not abruptly discontinue opioids in a patient
Post by admin » Tue Apr 09, 2019 11:02 pm
Link: | |
BBcode: | |
HTML: | |
Hide post links |
Return to “The FDA the good bad and the ugly”
Jump to
- Intractable Pain Explained
- Intractable Pain Act Being Repealed and Modified
- China's Covert War with Fentanyl and Carfentanil on the US Public
- The United Nations on the Overdose Crisis
- Stories of Chronic Pain
- CBD Products
- Opioid Crisis - Is the end Really Coming - Will There Be Justic For CPP'S
- AMA Opioid Task Force
- Investigations and Pain Management Denial Deaths
- Pain Management Clinics
- Hospitals Giving Tylenol After Major Surgery - Including Real Stories
- ↳ Pennsylvania Hospitals and Surgical Centers
- ↳ Commonwealth Health Wilkes-Barre General Hospital
- Medications and Drug Testing
- The Media's Intentional Fake News Narrative on the Opioid Crisis
- The Media Stories Starting to Report The Truth
- WHO, HRW, and UN - With The Lack of pain relief harm is being done.
- Carfentanil and its Fentanyl Analogs, not Prescription Fentanyl Killing Unsuspecting Drug Users.
- CDC Centers for Desiease Control Manipulation of the Intractable Pain Patients and Doctors
- Health and Human Services "HHS" Interfeering in Dr Patient Relationships leading to suicides
- National Institutes of Health nih.gov
- Medicare Is Cracking Down on Opioids
- THe DEA and it's involvement in Patient Abuse and Violation of Human Rights
- Government - Congress - House - New Laws
- Don't Punish Pain Rally Organization
- Pharmacies - Their Involvement and News of Help
- legal precedents used in the #Starburst complaint
- Opioid Crisis Govenment Hypocrisy
- Petitions & Letter to our Elected Officials (Important)
- Patient Abuse and Doctors Intentional Torture and Sufferin
- Veterans committing suicide over the VA's no Opioid policy
- Suffering without enough Pain Medications due to the DEA behavior
- The FDA the good bad and the ugly
- About Andrew Kolodny MD - Chair of Psychiatry & Self Proclaimed Opioid Expert
- YouTube & Media Videos Telling and Talking about the truth of the Opoid Crisis
- The Suicides Deaths have spiked as Forced Tapers continue
- CDC and FDA trying to explain their sadistic policies.
- Drug Abuse - Addiction v.s Dependance
- Chronic Illness Advocacy Awareness Group
- With the FDA & CDC in contradictions with the DEA Enforcers people are taking Desperate Measures
- What to know about Buprenorfine, Belbuca and the addiction drug Saboxone
- Doctors Making The Ultimate Sacrifice to help those in Chronic Pain
- State Programs - Tapering - Processes - Ruling - Started After The 90 MME
- National Council on Independent Living and others Supporters
- Support CPP's - Donate - Help The Cause